ERBB2 and breast carcinoma: Our results showed that the combination of trastuzumab and neratinib treatment was significantly more potent at reducing cell viability than trastuzumab alone in both sensitive and acquired resistant HER2 over-expressing SKBR3 and BT474 breast cancer cells.